---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-203755"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2024-08-20T23:59:59+00:00"
generated_at: "2026-05-31T08:29:54.627881+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kymera prices $225M offering of common stock and pre-funded warrants

## Summary
- Selling 2,002,313 shares at $40.75 and 3,519,159 pre-funded warrants at $40.7499.
- Net proceeds estimated at ~$246.5M after underwriting discounts and expenses.
- Underwriters exercised 30-day option to purchase additional 828,220 shares in full.
- Proceeds to advance preclinical and clinical degrader programs and for working capital.
- Existing cash plus offering proceeds expected to fund operations into mid 2027.

## SEC filing metadata
- accession: 0001193125-24-203755
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2024-08-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312524203755/0001193125-24-203755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312524203755/d846843d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-203755
- JSON: https://secwatch.observer/filing/0001193125-24-203755.json
- Plain text: https://secwatch.observer/filing/0001193125-24-203755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.